What is Seaport Therapeutics, Inc. Common Stock (SPTX)?

Seaport Therapeutics, Inc. Common Stock (SPTX) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of SPTX?

The current price of SPTX is $19.60. Prices are updated in real time on Stocks360.

What is SPTX's price-to-earnings (PE) ratio?

SPTX's trailing twelve-month PE ratio is -11.88, based on current price and earnings per share data available on Stocks360.

What is SPTX's market capitalization?

SPTX's market capitalization is $1,049,198,780.00, placing it in the small-cap tier.

Seaport Therapeutics, Inc. Common Stock (SPTX)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$19.60

Market Cap

$1.05B

PE (TTM)

-11.88

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.13

Day Range

$19.00 – $21.16

52-wk Range

$14.85 – $28.38

Avg Volume

N/A

Volume

549.18K

Seaport Therapeutics, Inc. Common Stock (SPTX) is a publicly traded company in the Healthcare sector. Latest price: $19.60. Market cap $1.05B. Trailing PE -11.88. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2026-05-01 · $19.84 2026-10-30 · $19.60 (-1.21%)

Earnings

Most Recent

Aug 3, 2026

EPS $-1.78 vs est. $-0.62

Missed by $1.16

Next Earnings

Nov 2, 2026

EPS estimate $-0.58

Proprietary Signals

Signal snapshot temporarily unavailable.

About Seaport Therapeutics, Inc. Common Stock

Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology. This exclusive platform is engineered to allow for oral administration of drugs, circumventing initial metabolic processing in the liver, and thereby reducing the risk of liver enzyme elevations, hepatotoxicity, and other potential adverse reactions. Every therapeutic agent in their pipeline incorporates this advanced platform, with all research and development efforts exclusively dedicated to neuropsychiatric applications. Founded in 2024 and situated in Boston, Massachusetts, the company connects with medical professionals and influential experts across the healthcare and neuropsychiatric sectors.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-11.88×
P/S (TTM)	0.00×
P/B	2.48×
P/FCF (TTM)	-22.65×
EV / EBITDA	-10.69×
EV / Sales	0.00×
Earnings Yield	-8.39%
Free Cash Flow Yield	-4.41%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$989.99M
Net Income (TTM)	-$88.01M
Free Cash Flow (TTM)	-$46.31M
Net Debt	-$59.21M
Working Capital	$266.50M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	-57.34%
Return on Invested Capital	-21.83%